Dihexa for Vitamin B12 Deficiency Brain Fog: The UCSF "Normal B12" Study, Homocysteine, Methylation & the 2026 UK Review

"Brain fog" — difficulty concentrating and short-term memory loss — is listed in NICE guideline NG239 as a recognised symptom of vitamin B12 deficiency, and in 2026 the link looks stronger, not weaker. In May 2026, a UC San Francisco team reported in Annals of Neurology that older adults with "normal" but lower levels of biologically active B12 already showed slower thinking, slower visual processing and more white-matter brain injury on MRI — even though their average total B12 (414.8 pmol/L) sat far above the 148 pmol/L deficiency cut-off. The biology is well understood: B12 powers the methylation reactions that build myelin and neurotransmitters, and deficiency raises homocysteine, which lowers the SAM:SAH ratio, drives DNA hypomethylation in the hippocampus and suppresses neurotrophic signalling — the same BDNF-TrkB endpoint that Dihexa, a positive modulator of HGF/c-Met synaptogenesis, also reaches. That overlap is exactly why people ask whether a synaptogenic peptide belongs in the conversation. This 2026 UK review walks through the new UCSF data, the homocysteine-methylation mechanism, the VITACOG brain-atrophy trial, who is at risk (pernicious anaemia, metformin, PPIs, vegans, malabsorption), and where Dihexa actually sits — which is behind a £5 blood test and a course of B12, not in front of it.

Vitamin B12 Deficiency and Brain Fog in 2026: A Common, Testable, Treatable Cause

Vitamin B12 (cobalamin) is a water-soluble vitamin the body cannot make and must obtain from animal foods or supplements. It is a cofactor for just two human enzymes, but both sit at the heart of brain biochemistry: methionine synthase, which regenerates methionine from homocysteine and feeds the universal methyl donor S-adenosylmethionine (SAM), and methylmalonyl-CoA mutase, which is needed for normal fatty-acid and myelin metabolism. When B12 runs low, methylation reactions stall, homocysteine accumulates, and myelin — the insulating sheath around nerve fibres — is laid down and maintained poorly. The clinical consequences span the haematological (a macrocytic anaemia), the neurological (peripheral neuropathy, subacute combined degeneration of the spinal cord) and the cognitive (slowed thinking, poor concentration, memory complaints) — the cluster patients describe as "brain fog".

That cognitive symptom is not folklore. The UK's NICE guideline NG239, published in 2024 to cover the diagnosis and management of B12 deficiency in over-16s, explicitly lists cognitive difficulties such as difficulty concentrating or short-term memory loss (sometimes described as "brain fog") among the common signs and symptoms — while noting they can also reflect delirium or dementia and so need proper assessment. The NHS overview of B12 and folate deficiency anaemia says much the same in plainer language: psychological and cognitive symptoms, including problems with memory, understanding and judgement, are part of the picture.

What makes B12 deficiency unusual among the conditions reviewed on this site is how tractable it is. It is detected with an inexpensive blood test, treated with cheap and widely available B12 (by injection where absorption is the problem, or orally where it is not), and — when caught early — frequently reversible. NICE NG239 tells clinicians to explain to patients that symptoms can start to improve within about two weeks of starting treatment, though full resolution may take three months or considerably longer. That combination — common, testable, treatable, and dangerous if missed — is the backdrop against which any question about an unlicensed peptide has to be judged.

The patient-facing question echoes the one running through the autoimmune-and-cognition posts elsewhere on this site — Hashimoto's thyroiditis, coeliac disease and mild cognitive impairment: "my brain fog has a real, documented biological cause — does something like Dihexa belong anywhere in the conversation?" In B12 deficiency, more than almost anywhere, the honest answer turns on a single fact: the cause is a missing vitamin, and you can simply put it back.

The May 2026 UCSF Study: "Normal" B12 May Not Be Enough

The most important new piece of evidence in this area — and the reason B12 and the brain were back in the headlines in 2026 — is a University of California, San Francisco study led by senior author Ari J. Green and co-first authors Alexandra Beaudry-Richard and Ahmed Abdelhak, published in Annals of Neurology (2025; 97(6): 1190; DOI 10.1002/ana.27200). The researchers enrolled 231 healthy older adults through the Brain Aging Network for Cognitive Health (BrANCH) study, with an average age of 71 and — importantly — none of whom had dementia or mild cognitive impairment.

The provocative finding is in the numbers. The participants' average blood B12 was 414.8 pmol/L — almost three times the US deficiency cut-off of 148 pmol/L. By the standard test, every one of them was comfortably "normal". But instead of relying on total B12, the team focused on the biologically active fraction — the portion the body can actually use. After adjusting for age, sex, education and cardiovascular risk factors, participants with lower active B12 had:

• Slower processing speed on cognitive testing, with the effect more pronounced at older ages;
• Delayed responses to visual stimuli, pointing to slower visual processing and reduced signalling efficiency; and
• A higher volume of white-matter lesions on MRI — areas of brain injury that have themselves been linked to cognitive decline, dementia and stroke.

White matter is the brain's wiring — the myelinated nerve fibres that let regions communicate — and myelin is precisely what B12-dependent methylation helps build and maintain. A signal showing up in white matter is therefore mechanistically coherent rather than incidental. As Green put it, "previous studies that defined healthy amounts of B12 may have missed subtle functional manifestations… revisiting the definition of B12 deficiency to incorporate functional biomarkers could lead to earlier intervention and prevention of cognitive decline." Beaudry-Richard added that low-but-normal B12 "could impact cognition to a greater extent than what we previously thought, and may affect a much larger proportion of the population than we realise."

For evidence-graded longevity and neuroprotection research relevant to this condition, see the Longevity Stack research library.

Total B12, Active B12, MMA and Homocysteine: Why the Test Matters

One reason B12 deficiency is so often missed — and why people with genuine symptoms are sometimes told their levels are "fine" — is that the routine test is a blunt instrument. Most circulating B12 is bound to a protein called haptocorrin and is not available to tissues. Only the fraction bound to transcobalamin — measured as active B12, or holotranscobalamin (holoTC) — is delivered to cells. A "normal" total B12 can therefore sit on top of an inadequate active fraction, exactly the gap the UCSF study exploited.

Two functional markers close the gap further, because they rise specifically when cells are B12-starved:

• Methylmalonic acid (MMA) accumulates when the B12-dependent enzyme methylmalonyl-CoA mutase cannot do its job. A raised MMA is a sensitive sign of true cellular B12 deficiency.
• Homocysteine accumulates when methionine synthase — the other B12-dependent enzyme — stalls. It rises in both B12 and folate deficiency, and (as the next section explains) it is not merely a marker but an active participant in the brain injury.

NICE NG239 reflects this complexity: where the clinical picture and the total B12 disagree, additional testing — including active B12 or MMA in some pathways — helps resolve indeterminate results, and the diagnosis is ultimately clinical rather than a single number. The practical message for anyone with brain fog who has been reassured by a borderline result is to ask specifically about active B12, MMA and homocysteine, and about folate and ferritin alongside — not to conclude that a "normal" total B12 has ruled the vitamin out.

The Homocysteine–Methylation Mechanism: How Low B12 Reaches the Synapse

For the Dihexa-specific question, the decisive biology is the chain that links a missing vitamin to a malfunctioning synapse — and it runs through homocysteine and DNA methylation.

When B12 is scarce, methionine synthase slows, homocysteine builds up, and less methionine is converted to S-adenosylmethionine (SAM), the body's universal methyl donor. At the same time, homocysteine is metabolised to S-adenosylhomocysteine (SAH), a potent inhibitor of methyltransferase enzymes. The result is a fall in the SAM:SAH ratio — a state of "hypomethylation" that ripples across the epigenome. Methylation is how the brain switches genes on and off, builds neurotransmitters and maintains myelin; degrade it and many downstream systems wobble at once.

The hippocampal consequences are now reasonably well mapped in experimental work. Elevated homocysteine has been shown to disrupt neurotrophic and inflammatory circuits in the hippocampus — lowering levels of neurotrophic factors including TrkB (the BDNF receptor), VEGF and EGF while raising inflammatory markers. Other work shows homocysteine driving blood-brain-barrier disruption and cognitive decline via DNA hypomethylation of the calcium-channel gene Cav1.2, and restraining hippocampal neurogenesis by inhibiting DNA methylation. In short, the homocysteine that piles up in B12 deficiency is not a passive flag — it actively suppresses the neurotrophic, vascular and plasticity machinery the brain needs to think clearly.

This matters for two reasons. First, it explains why B12 deficiency produces a genuine, mechanism-backed brain fog rather than an imagined one. Second, it pinpoints exactly where the convergence with Dihexa's pharmacology lies: the end-state of the homocysteine cascade is reduced BDNF-TrkB signalling, impaired synaptic plasticity and a compromised blood-brain barrier — the same triad Dihexa's HGF/c-Met mechanism is claimed to support. We return to that overlap, and its limits, after the treatment evidence.

What the Treatment Evidence Actually Shows: VITACOG and the Limits of Supplementation

If homocysteine is doing the damage, can lowering it — with the B vitamins (B12, B6 and folate) that metabolise it — protect the brain? The most important trial here is VITACOG, an Oxford-led, double-blind, placebo-controlled study in older adults with mild cognitive impairment.

Smith and colleagues (2010, PLOS One) randomised participants to high-dose B vitamins (0.8 mg folic acid, 0.5 mg B12 and 20 mg B6) or placebo for two years and found that the treatment slowed the rate of whole-brain atrophy, with the effect greatest in those who started with the highest homocysteine. A follow-up imaging analysis, Douaud et al. (2013, PNAS), showed the B vitamins slowed grey-matter atrophy by around 30% — specifically in the brain regions vulnerable to Alzheimer's disease — and again, the benefit was concentrated in participants with raised homocysteine. This is the strongest evidence that, in the right people, addressing the B12/homocysteine axis has a structural, not just symptomatic, effect on the brain.

But the honest picture requires the counter-evidence too, and 2025 added plenty. A 2025 systematic review and meta-analysis of randomised trials found that supplementing B6, B9 or B12 produced only a very small benefit in global cognition among older adults overall — not a dramatic boost for everyone. A 2025 Mendelian-randomisation study found no clear evidence that genetically higher total serum B12 protects the general population from psychiatric disorders or cognitive impairment — though the authors flagged that they measured total, not active, B12. And a 2025 comprehensive review concluded that B12 deficiency remains a genuinely modifiable risk factor for cognitive problems — especially in high-risk groups such as older adults and vegetarians — while calling for better biomarkers and imaging to catch it earlier.

Who Gets B12 Deficiency Brain Fog: The Risk Groups That Matter

B12 brain fog is not random. It clusters in identifiable groups, and recognising yourself in one of them is a far more useful step than any self-experiment.

Pernicious anaemia and autoimmune gastritis

The classic cause of severe B12 deficiency is pernicious anaemia — an autoimmune attack on the stomach's parietal cells and on intrinsic factor, the protein needed to absorb B12 in the ileum. NICE NG239 specifically covers deficiency caused by autoimmune gastritis. Because it is an absorption problem, it generally requires lifelong B12 injections, not oral tablets, and it clusters with other autoimmune conditions — including the autoimmune thyroid disease reviewed elsewhere on this site. Anyone with brain fog and a personal or family history of autoimmune disease should have B12 and intrinsic-factor antibodies considered.

Metformin, PPIs and other drugs

Long-term metformin, the first-line drug for type 2 diabetes, reduces B12 absorption and is a well-documented cause of deficiency — an important overlap, because diabetic brain fog and B12 brain fog can coexist in the same person. Proton pump inhibitors (PPIs) and H2-blockers reduce the stomach acid needed to liberate B12 from food, and long-term use lowers B12 over time. These drug effects are common, under-recognised and entirely correctable once spotted.

Malabsorption and gastrointestinal surgery

Anything that damages the stomach or ileum impairs B12 handling: coeliac disease and other malabsorptive conditions, Crohn's disease, and gastric or ileal resection (including some bariatric surgery). Where coeliac disease causes a multi-nutrient malabsorption — iron, folate, vitamin D and B12 together — the brain fog is genuinely multifactorial.

Vegan and vegetarian diets

B12 occurs naturally only in animal foods, so people following vegan or strict vegetarian diets without reliable supplementation or fortified foods are at clear risk — one of the high-risk groups the 2025 review singled out. This is the most easily prevented cause: a modest oral supplement is sufficient when absorption is intact.

Older adults

Absorption becomes less efficient with age, partly through age-related atrophic gastritis, which is why the UCSF study focused on older adults and why low-but-"normal" B12 may be quietly affecting cognition in a sizeable slice of the population. Age alone is not, in NICE's framing, a reason to test — but age plus symptoms or another risk factor is.

The reason this list matters to the Dihexa question is simple: each entry points to a specific, treatable action — switch or supplement around a drug, treat the malabsorption, start injections for pernicious anaemia, add an oral B12 to a vegan diet. None of those actions is "take a synaptogenic peptide", and none of them is replaced by one.

The BDNF–HGF–c-Met Chain: Where Dihexa Enters the Picture

With the deficiency biology in place, the molecular overlap with Dihexa is easy to state — and easy to over-read. The homocysteine cascade of B12 deficiency converges on reduced hippocampal BDNF-TrkB signalling, impaired long-term potentiation, suppressed VEGF/EGF-driven cerebrovascular support and a leakier blood-brain barrier. Those are, point for point, the systems Dihexa's mechanism is claimed to support.

Hippocampal BDNF binds the TrkB receptor and drives dendritic-spine maturation, LTP and memory consolidation. Independently, HGF/c-Met signalling drives synaptogenesis through the PI-3K/AKT and MAPK pathways — a parallel track to the same cellular outcome — and, unusually for a procognitive mechanism, it also supports cerebrovascular angiogenesis and blood-brain-barrier integrity. A 2021 Frontiers in Cell and Developmental Biology review details how MET expression in the cortex sustains adult synaptogenesis and angiogenesis.

Dihexa — a small peptide analogue derived from angiotensin IV — is a positive modulator of the HGF/c-Met pathway. Full detail is on the mechanism of action page; the foundational pharmacology is Benoist et al. (2014, JPET). Its relevance to B12 brain fog rests on three points of overlap — and three matching caveats:

• Synaptogenesis as a parallel route to plasticity. When homocysteine-driven hypomethylation suppresses BDNF-TrkB signalling, a pathway that pushes synaptogenesis from a different axis is conceptually interesting. Caveat: the word is conceptually — there are no B12-deficiency data for Dihexa at all.
• Cerebrovascular and BBB support as a parallel route to perfusion. Homocysteine damages the blood-brain barrier and suppresses VEGF/EGF; HGF/c-Met has a documented vascular component. Caveat: mechanism is not evidence, and the homocysteine that does the damage falls when you replace the B12.
• The directionality problem is decisive. In B12 deficiency the upstream driver — a missing vitamin and the homocysteine it lets accumulate — is removable. Pushing synaptogenesis downstream while the methylation cycle is still broken and homocysteine is still high is biologically back-to-front. The intervention that fixes the cause is B12, not a peptide layered on top of an unresolved deficiency.

This is the genuine mechanistic case for being curious about Dihexa here. The rest of the article is about why curiosity is not evidence — and why, in B12 deficiency specifically, the existence of a cheap definitive treatment makes the case for an unlicensed peptide weaker than almost anywhere else on this site.

Replacement First: The Only Evidence-Based Treatment

Any honest review of B12 brain fog has to begin with B12 replacement, because it is not merely first-line — it is the only treatment with an evidence base, and it is disease-modifying rather than cosmetic. Correcting B12 restarts methionine synthase, lowers homocysteine, restores the SAM:SAH ratio and rebuilds myelin. Where the problem is absorption — pernicious anaemia, post-surgical, ileal disease — this means intramuscular hydroxocobalamin injections, typically a loading course followed by maintenance; where absorption is intact (most dietary deficiency), appropriate oral B12 can suffice.

Several practical points follow, and they map closely onto the gluten-free-diet logic in the coeliac review:

• Check folate and treat B12 first. Giving folic acid to someone who is B12-deficient can correct the anaemia while masking it and allowing neurological damage to progress. B12 status must be established before high-dose folate — a classic, important trap.
• Find out why. Replacement treats the deficiency; it does not explain it. Pernicious anaemia, coeliac disease, drug effects and diet each need their own follow-up, and pernicious anaemia means lifelong treatment.
• Recovery takes time, and timing matters. NICE NG239 sets expectations: some improvement within two weeks, fuller recovery over up to three months, and longer still in long-standing cases. Severe, neglected deficiency with cord involvement may recover only partially — which is the whole argument for testing early.
• Lower the homocysteine. Folate and B6 alongside B12 normalise homocysteine; VITACOG suggests that, in those with raised homocysteine and MCI, this has a measurable structural payoff.

Notice what is absent from that list: any role for a synaptogenic peptide. That is not an oversight — it is where the evidence sits.

When Brain Fog Persists Despite B12 Replacement

Some people continue to feel foggy after their B12 is corrected, and this is the scenario in which the temptation to reach for something like Dihexa is strongest. Before any unlicensed compound, structured assessment is far more likely to find a treatable answer:

• Inadequate or wrong-route replacement. Oral B12 in someone with an absorption problem won't work; injection frequency may be insufficient. Re-checking active B12, MMA and homocysteine confirms whether replacement is actually doing its job.
• Co-existing deficiencies. Iron (ferritin) and folate often travel with B12 deficiency, especially in malabsorption; each independently causes brain fog and each needs correcting.
• Irreversible damage. Long-standing deficiency can leave residual neuropathy or cord changes; this needs neurological assessment, not a peptide.
• A second diagnosis. B12 deficiency commonly coexists with thyroid disease, depression, anxiety, menopause and sleep disorders — any of which can independently sustain cognitive symptoms.
• The "normal but not optimal" zone. Per the UCSF data, some people with replaced-but-low-active B12 may still be functionally short; this is a conversation about optimising replacement and lowering homocysteine with a clinician, not about experimental chemistry.

The point is the same as ever: persistent B12 brain fog almost always has a findable, treatable explanation that an unlicensed peptide would do nothing to address — and might obscure.

B12-Specific Risks of Dihexa Use

Beyond the general safety considerations on the side effects page, B12 deficiency raises specific concerns.

Masking irreversible damage. This is the central, and uniquely sharp, risk. Untreated B12 deficiency does not merely cause reversible fog; it can progress to subacute combined degeneration of the spinal cord and peripheral neuropathy, which may not fully recover. Anything that produces a subjective lift — placebo included — while the deficiency goes uncorrected is genuinely dangerous, because it delays the cheap test and the cheap treatment that prevent permanent harm. In few conditions is masking this consequential.

The folate-trap, restated. The instinct to "support cognition" with supplements or compounds before establishing B12 status is exactly the error that high-dose folate represents — correcting surface signs while nerve damage continues underneath. A peptide aimed at the downstream synapse, taken instead of checking B12, is the same mistake in a more expensive form.

The general c-Met / oncology caution. The standard Dihexa concern applies: c-Met activation is implicated in tumour growth and invasion across several cancers, so anyone with a personal or family history of c-Met-relevant cancers should not consider Dihexa for any indication — B12 brain fog included.

Unknown product quality and interactions. Unlicensed research chemicals carry no guarantee of composition, purity or labelling, and there are no pharmacokinetic data for Dihexa in anyone, let alone in a person with malabsorption. None are likely to exist.

The Fosgonimeton Parallel and the Limits of Mechanism

The most instructive cautionary tale for any HGF/c-Met-based cognitive claim is fosgonimeton (ATH-1017), Athira Pharma's HGF/MET positive modulator and the closest clinical-stage relative to Dihexa. Fosgonimeton was a genuine, injectable, clinically tested drug developed specifically to enhance HGF/c-Met signalling for cognition — exactly the mechanism Dihexa is promoted on. In 2024 it missed its primary endpoint in the Phase 3 LIFT-AD Alzheimer's trial.

The lesson is not that HGF/c-Met is irrelevant to cognition; it is that a coherent, well-funded, professionally executed attempt to turn that mechanism into clinical benefit failed its definitive test. If a purpose-built drug with proper trials could not convert the mechanism into measurable cognitive benefit in a defined population, the case for an unlicensed research chemical converting the same mechanism into benefit in B12 brain fog — a condition that already has a cheap, definitive treatment — is weaker still. Mechanism-first reasoning is a hypothesis generator, not evidence.

Who Should Not Consider Dihexa for B12 Brain Fog

Bringing the threads together, Dihexa should not be considered by:

• Anyone who has not had B12 (ideally with active B12, MMA and homocysteine), folate and ferritin checked — the blood test comes first, always.
• Anyone with confirmed deficiency who has not completed proper replacement and had the cause investigated (pernicious anaemia, coeliac, drug effect, diet).
• Anyone with tingling, numbness, balance problems or other neurological signs — these need urgent assessment for nerve or cord involvement, not a peptide trial.
• Anyone with a personal or family history of breast, ovarian, lung, gastric or other c-Met-relevant cancers.
• Anyone who is pregnant, breastfeeding or trying to conceive — B12 and folate status are critical in pregnancy, and Dihexa has no reproductive safety data.
• Anyone whose cognitive symptoms have not been distinguished from comorbid thyroid disease, depression or anxiety.

What the Evidence Actually Supports for B12 Brain Fog in 2026

Stripped to essentials, the evidence-based approach to B12 brain fog is cheap, fast and effective:

• Test properly. B12 with active B12 / MMA / homocysteine where the picture is borderline, plus folate and ferritin — don't be reassured by a "normal" total B12 if symptoms fit.
• Replace the B12. Injections for pernicious anaemia and malabsorption; appropriate oral B12 for dietary deficiency with intact absorption. Treat B12 before high-dose folate.
• Find and fix the cause. Autoimmune gastritis, coeliac disease, metformin, PPIs or diet — each has its own correctable action.
• Lower homocysteine. B12, folate and B6 together; VITACOG suggests a structural payoff in those with raised homocysteine and MCI.
• Allow time, then reassess. Improvement begins within weeks; if fog persists after proper replacement, look for co-deficiency, residual damage or a second diagnosis — not a peptide.
• Treat the comorbidity. Thyroid, mood, sleep and other contributors each independently worsen cognition and each has evidence-based treatment.

What is absent from that list is any role for an unlicensed synaptogenic peptide — an honest reflection of where the evidence sits in 2026.

The Bottom Line in 2026

B12 deficiency brain fog is real, biological and unusually well understood. NICE NG239 recognises the cognitive symptom; the homocysteine–methylation cascade explains how a missing vitamin reaches the synapse, suppressing hippocampal neurotrophins and degrading the blood-brain barrier; VITACOG shows that lowering homocysteine can slow brain atrophy in the right people; and the May 2026 UCSF study suggests the effects begin even at "normal" B12 levels. The biology converges on reduced BDNF-TrkB plasticity and compromised cerebrovascular support — the same downstream endpoint Dihexa's HGF/c-Met pharmacology reaches.

But B12 deficiency is the condition where mechanism-first reasoning is at its very weakest, for one reason: the upstream cause is a missing vitamin you can simply replace. Correcting B12 lowers the homocysteine, restarts the methylation cycle and, caught early, lifts the fog — cheaply and definitively. The honest reading of the 2026 evidence is therefore: test first, replace second, find the cause third, lower homocysteine and treat comorbidity fourth, and research chemicals essentially last — if at all. With new data pushing toward functional biomarkers and earlier detection, the momentum in this field is toward catching the deficiency sooner, not reaching past it for an unproven peptide. In a condition that can cause permanent nerve damage if ignored, that distinction is not academic — it is the whole point.

Frequently Asked Questions

Related Reading on Dihexa.co.uk

• Dihexa vs Omega-3 & Fish Oil for Brain Fog (2026) — another foundational nutrient for the ageing brain: DHA, EPA and the Framingham red-blood-cell DHA dementia data.
• Dihexa for Vitamin D Deficiency Brain Fog (2026) — the sibling deficiency that frequently coexists with low B12, and the 2026 midlife vitamin D–tau study.
• Dihexa for Magnesium Deficiency Brain Fog (2026) — the NMDA-receptor mineral behind the 2025 magnesium L-threonate cognition trial, and another nutrient PPIs and metformin deplete.
• Dihexa for Coeliac Disease & Gluten Brain Fog (2026) — malabsorption that causes combined B12, iron and folate deficiency.
• Dihexa for Hashimoto's & Hypothyroid Brain Fog (2026) — pernicious anaemia clusters with autoimmune thyroid disease.
• Dihexa for Diabetic Brain Fog (2026) — long-term metformin is a leading cause of B12 depletion.
• Dihexa for MCI & Brain Aging (2026) — the population VITACOG studied; the BDNF-TrkB endpoint B12 brain fog shares.
• Dihexa for Vascular Dementia (2026) — homocysteine, white-matter disease and cerebrovascular cognition.
• Dihexa for Menopause Brain Fog (2026) — another condition where treatable causes dominate.
• Dihexa for Depression & Mood (2026) — B12 deficiency and low mood frequently coexist.
• Dihexa for ME/CFS (2026) — the fatigue-and-fog overlap where B12 should always be checked.
• Dihexa vs BDNF: What "10 Million Times More Potent" Actually Means — in-depth look at the BDNF mechanism claim.
• Mechanism of Action — HGF/c-Met, PI-3K/AKT, dendritic spines, cerebrovascular angiogenesis.
• Side Effects & Risks — the general safety picture.
• UK Legal Status — where Dihexa sits in UK law and MHRA advertising rules.
• Fosgonimeton & Athira — the cautionary Phase 3 story.

External Authoritative Sources Cited

• UC San Francisco / ScienceDaily (22 May 2026). "Normal" vitamin B12 levels may still leave older adults vulnerable to hidden brain damage and cognitive decline.
• Beaudry-Richard A, Abdelhak A, … Green AJ (Annals of Neurology, 2025; 97(6):1190). Vitamin B12 Levels Association with Functional and Structural Biomarkers of CNS Injury in Older Adults. DOI 10.1002/ana.27200.
• NICE NG239 — Vitamin B12 deficiency in over 16s: diagnosis and management (2024).
• NICE NG239 — Recommendations (signs, symptoms and testing for B12 deficiency).
• NHS — Vitamin B12 or folate deficiency anaemia overview.
• Smith AD et al. (PLOS One, 2010). Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment (VITACOG).
• Douaud G et al. (PNAS, 2013). Preventing Alzheimer's disease-related grey matter atrophy by B-vitamin treatment.
• Homocysteine-driven disruption of neurotrophic and inflammatory circuits in the hippocampus (2025).
• Homocysteine drives hippocampal blood-brain barrier disruption and cognitive decline via DNA hypomethylation of Cav1.2 (Brain Sciences, 2026).
• Homocysteine restrains hippocampal neurogenesis by inhibiting DNA methylation (Neurochemistry International, 2021).
• Systematic review and meta-analysis of B-vitamin supplementation and cognition in older adults (Nutrition Reviews, 2025).
• Mendelian randomisation of serum vitamin B12 and psychiatric / cognitive outcomes (Communications Medicine, 2025).
• Vitamin B12 deficiency and cognitive impairment: a comprehensive review of neurological impact (Brain Disorders, 2025).
• HGF and MET in brain development and neurological disorders (Frontiers in Cell and Developmental Biology, 2021).
• Benoist CC et al. (JPET, 2014). Dihexa procognitive effects via HGF/Met.